You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華領醫藥(2552.HK)宣佈與國藥控股簽署供應鏈戰略合作協議,商業化佈局進一步提速
格隆匯 09-15 13:12

格隆匯9月15日丨國內領先的生物技術公司華領醫藥(2552.HK)宣佈與國藥控股(1099.HK)簽署供應鏈戰略合作協議。華領醫藥創始人、CEO陳力博士,營銷戰略和市場部副總裁徐文潔女士,國藥控股總裁劉勇先生,副總裁周旭東等出席了簽約儀式。

根據協議,雙方將藉助華領醫藥在醫藥創新能力方面和國藥控股在渠道網絡、供應鏈體系和物流資源等方面的優勢,增強多格列艾汀上市後的產品可及性,包括提升患者用藥服務能力和擴展渠道市場覆蓋範圍,更加廣泛地造福中國患者,推進糖尿病精準治療和全生命週期管理,同時全面服務“健康中國2030”戰略。

國藥控股將利用其覆蓋全國的渠道網絡和供應鏈資源等優勢,為華領提供專業化的醫藥物流服務;華領醫藥將依託國藥控股的全國藥品分銷網絡,在供應鏈管理等方面展開深入合作;在此基礎上,雙方還將在渠道信息化等方面,拓展進一步深度合作的可能性。

此次與國藥的戰略合作是今年華領在商業化方面又一好消息,今年3月華領醫藥正式向國家藥品監督管理局遞交了多格列艾汀用於治療2型糖尿病的新藥上市申請,並於4月獲得受理。此外,華領還將在上海臨港新片區設立生產基地,以確保多格列艾汀充足的商業供應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account